Abstract:Alzheimer's disease (AD), a multi-factorial neurodegenerative disorder has affected over 30 million individuals globally and these numbers are expected to increase in the coming decades. Current therapeutic interventions are largely ineffective as they focus on a single target. Development of an effective drug therapy requires a deep understanding of the various factors influencing the onset and progression of the disease. Aging and genetic factors exert a major influence on the development of AD. Other factors like post-viral infections, iron overload, gut dysbiosis, and vascular dysfunction also exacerbate the onset and progression of AD. Further, post-translational modifications in tau, DRP1, CREB, and p65 proteins increase the disease severity through triggering mitochondrial dysfunction, synaptic loss, and differential interaction of amyloid beta with different receptors leading to impaired intracellular signalling. With advancements in neuroscience tools, new inter-relations that aggravate AD are being discovered including pre-existing diseases and exposure to other pathogens. Simultaneously, new therapeutic strategies involving modulation of gene expression through targeted delivery or modulation with light, harnessing the immune response to promote clearance of amyloid deposits, introduction of stem cells and extracellular vesicles to replace the destroyed neurons, exploring new therapeutic molecules from plant, marine and biological sources delivered in the free state or through nanoparticles and use of non-pharmacological interventions like music, transcranial stimulation and yoga. Polypharmacology approaches involving combination of therapeutic agents are also under active investigation for superior therapeutic outcomes. This review elaborates on various disease-causing factors, their underlying mechanisms, the inter-play between different disease-causing players, and emerging therapeutic options including those under clinical trials, for treatment of AD. The challenges involved in AD therapy and the way forward have also been discussed.

Genetic Risk, Inflammation, and Therapeutics: An Editorial Overview of Recent Advances in Aging Brains and Neurodegeneration

Inflammaging and Brain Aging

Advances in gene therapy approaches targeting neuro-inflammation in neurodegenerative diseases

Recent Insights into the Neurobiology of Alzheimer's Disease and Advanced Treatment Strategies

Inflammation, Autoimmunity and Neurodegenerative Diseases, Therapeutics and Beyond

New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists

Dietary phytochemicals and neuro-inflammaging: from mechanistic insights to translational challenges.

Recent Advances in the Synthesis of Antioxidant Derivatives: Pharmacological Insights for Neurological Disorders

Neuroinflammation: A Critical Factor in Neurodegenerative Disorders

Underlying Mechanisms of Brain Aging and Neurodegenerative Diseases as Potential Targets for Preventive or Therapeutic Strategies Using Phytochemicals

Mechanistic insights and emerging therapeutic stratagems for Alzheimer's disease

Unveiling the Interplay of AMPK/SIRT1/PGC-1α axis in Brain Health: Promising Targets Against Aging and NDDs

Insights into Molecular, Cellular, and Systemic Mechanisms

An insight into the concept of neuroinflammation and neurodegeneration in Alzheimer's disease: targeting molecular approach Nrf2, NF-κB, and CREB

Therapeutics of Alzheimer's Disease: Recent Developments

Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets

Recent Research Trends in Neuroinflammatory and Neurodegenerative Disorders

Insights into the Pathogenesis of Neurodegenerative Diseases: Focus on Mitochondrial Dysfunction and Oxidative Stress

Neurodegenerative disorders: Mechanisms of degeneration and therapeutic approaches with their clinical relevance

The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets

Genetic Editing and Pharmacogenetics in Current And Future Therapy Of Neurocognitive Disorders